Ember Therapeutics to Present at Marcum MicroCap Conference

NEW YORK, May 31, 2016 (GLOBE NEWSWIRE) -- Ember Therapeutics, Inc. (OTCQB:EMBT), a New York-based biopharmaceutical company developing targeted therapies for osteoarthritis, kidney fibrosis, and other indications using Bone Morphogenetic Protein (BMP)-7, today announced that the Company is scheduled to present at the 2016 Marcum MicroCap Conference being held June 1-2, 2016 in New York, NY.

Details of the presentation are as follows:

Conference: 2016 Marcum MicroCap Conference
Date:Wednesday, June 1, 2016
Time:4:00 p.m. EDT
Location:Grand Hyatt New York, Broadway Room

About Ember Therapeutics, Inc.

Ember Therapeutics, Inc. is a clinical stage biopharmaceutical company whose primary focus is on utilizing Bone Morphogenetic Protein-7 to catalyze cartilage regeneration for disease modification of Osteoarthritis (OA) and the inhibition and reversal of organ fibrosis in diseases such as Chronic Kidney Disease (CKD) and Alport Syndrome. In particular, Ember has acquired over 450 patents covering BMP-7 and its related family of BMPs, variants, novel formulations, delivery technologies, associated clinical data, and cGMP manufactured material from Stryker Corporation. For more information, please visit www.embertx.com.

Contact The Ruth Group Lee Roth (investors) (646) 536-7012 lroth@theruthgroup.com

Source:Ember Therapeutics